COMMUNIQUÉS West-GlobeNewswire

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025

02/05/2025 - 08:30

Tokyo, Japan and Cambridge, UK, 2 May 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter ended 31 March 2025 [...]

Bavarian Nordic Receives Marketing Authorization for Chikungunya Vaccine for Persons Aged 12 and Older in the United Kingdom

02/05/2025 - 08:30

COPENHAGEN, Denmark, May 2, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization in the United Kingdom (UK) [...]

EnteroBiotix to Present Results from Phase 1b trial in Liver Cirrhosis at EASL Congress 2025

02/05/2025 - 09:00

Glasgow, Scotland – 2 May 2025. EnteroBiotix Limited (‘EnteroBiotix’), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that results from its IMPuLCE [...]

Orion Corporation: Managers’ transactions – Henrik Stenqvist

02/05/2025 - 10:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MAY 2025 at 11.45 EEST Orion Corporation: Managers’ transactions – Henrik Stenqvist Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) [...]

Orion Corporation: Managers’ transactions – Veli-Matti Mattila

02/05/2025 - 10:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MAY 2025 at 11.45 EEST Orion Corporation: Managers’ transactions – Veli-Matti Mattila Orion Corporation has received the following disclosure under Market Abuse Regulation (EU [...]

Orion Corporation: Managers’ transactions – Kari Jussi Aho

02/05/2025 - 10:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MAY 2025 at 11.45 EEST Orion Corporation: Managers’ transactions – Kari Jussi Aho Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]

Orion Corporation: Managers’ transactions – Karen Lykke Sørensen

02/05/2025 - 10:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MAY 2025 at 11.45 EEST Orion Corporation: Managers’ transactions – Karen Lykke Sørensen Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]

Orion Corporation: Managers’ transactions – Eija Ronkainen

02/05/2025 - 10:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MAY 2025 at 11.45 EEST Orion Corporation: Managers’ transactions – Eija Ronkainen Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]

Orion Corporation: Managers’ transactions – Ari Lehtoranta

02/05/2025 - 10:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MAY 2025 at 11.45 EEST Orion Corporation: Managers’ transactions – Ari Lehtoranta Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]

Orion Corporation: Managers’ transactions – Hilpi Rautelin

02/05/2025 - 10:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MAY 2025 at 11.45 EEST Orion Corporation: Managers’ transactions – Hilpi Rautelin Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No [...]

Orion Corporation: Managers’ transactions – Maziar Mike Doustdar

02/05/2025 - 10:45

ORION CORPORATION MANAGERS’ TRANSACTIONS 2 MAY 2025 at 11.45 EEST Orion Corporation: Managers’ transactions – Maziar Mike Doustdar Orion Corporation has received the following disclosure under Market Abuse Regulation ( [...]

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration

02/05/2025 - 10:59

Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD CHENGDU, China and ROCKAWAY, N.J., May 02, 2025 (GLOBE NEWSWIRE) -- Chengdu Origen Biotechnology Co., [...]

Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders

02/05/2025 - 07:00

Allschwil, Switzerland – May 2, 2025 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the [...]

301,521 Orion Corporation A shares converted into B shares

02/05/2025 - 08:00

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 2 MAY 2025 at 9.00 EEST 301,521 Orion Corporation A shares converted into B shares In accordance with Section [...]

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

02/05/2025 - 02:14

Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE ® FL-1 trial Full results from the trial will be [...]

OBI Pharma reçoit l’approbation de la FDA à la suite de sa demande d’étude clinique de la Phase I/II pour OBI-902, un CAM ciblant Trop-2

02/05/2025 - 04:56

OBI-902 est le premier CAM utilisant la technologie CAM brevetée GlycOBI® d’OBI TAIPEI, Taïwan, 02 mai 2025 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (« OBI »), un laboratoire d’oncologie au stade clinique (4174.TWO), [...]

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

01/05/2025 - 22:01

Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million Company ends Q1 with $214.0 [...]

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

01/05/2025 - 22:05

– Topline histology data from ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials are expected in 1H 2027 and in 2028, respectively; each trial is designed to support accelerated approval to treat patients with [...]

Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference

01/05/2025 - 22:05

WESTLAKE VILLAGE, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick , President, CEO and Chairman of the [...]